CN111773352A - Application of turmeric and plantain seed composition in preparation of pharmaceutical composition for reducing blood sugar and blood pressure - Google Patents

Application of turmeric and plantain seed composition in preparation of pharmaceutical composition for reducing blood sugar and blood pressure Download PDF

Info

Publication number
CN111773352A
CN111773352A CN201910896486.4A CN201910896486A CN111773352A CN 111773352 A CN111773352 A CN 111773352A CN 201910896486 A CN201910896486 A CN 201910896486A CN 111773352 A CN111773352 A CN 111773352A
Authority
CN
China
Prior art keywords
turmeric
plantain seed
extract
composition
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910896486.4A
Other languages
Chinese (zh)
Inventor
翁庆丰
傅耀贤
陈思霈
张嘉祥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen Medical College
Original Assignee
Xiamen Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen Medical College filed Critical Xiamen Medical College
Priority to CN201910896486.4A priority Critical patent/CN111773352A/en
Publication of CN111773352A publication Critical patent/CN111773352A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Abstract

The invention discloses application of a turmeric and plantain seed composition in preparing a pharmaceutical composition for reducing blood sugar and blood pressure, wherein the pharmaceutical composition is orally administered, and the turmeric and plantain seed composition consists of plantain seed crude drug powder or plantain seed extract and turmeric crude drug powder or turmeric extract. The turmeric and plantain seed composition has obvious curative effects on reducing blood sugar and blood pressure, and can be used for preparing effective pharmaceutical compositions for treating individuals suffering from diabetes (and) or hypertension.

Description

Application of turmeric and plantain seed composition in preparation of pharmaceutical composition for reducing blood sugar and blood pressure
Technical Field
The invention belongs to the technical field of Chinese patent medicines, and particularly relates to application of a turmeric and plantain seed composition in preparation of a pharmaceutical composition for reducing blood sugar and blood pressure.
Background
Current treatment of diabetes is divided into three components: regular exercise, diet control and medication. The medicinal treatment of diabetes is divided into oral hypoglycemic agent or insulin injection; when the blood sugar is still poorly controlled after oral hypoglycemic agent treatment, insulin injection therapy may be required instead. However, with the difference of the action mechanism of the medicine, the time of taking medicine is also different: firstly, the medicine is taken thirty minutes before a meal, is taken immediately before the meal or is taken along with the meal, and has the function of stimulating insulin secretion; secondly, the drugs taken after meals are used for improving insulin resistance and reducing glucose output of the liver, but the effect is mostly in the gastrointestinal tract, so that the side effect of gastrointestinal discomfort can be avoided when patients take the drugs after meals. Among the side effects of hypoglycemic drugs, hypoglycemia is the most common, especially when patients take drugs and are not matched with diet time or do not eat and engage in activities that consume blood sugar; secondly, gastrointestinal discomfort; in addition, hepatotoxicity may be caused.
Insulin for injection is the same as or almost the same as insulin produced in a human body, is widely used at present, can achieve the most effective treatment on diabetes, and reduces problems possibly caused by poor blood sugar control, such as pathological changes of eyes, kidneys and peripheral nerves. However, the injection position, injection depth, movement and dosage all affect the absorption of insulin. In order to obtain stable insulin absorption and action, attention must be paid to the fact that the injection frequency in the same injection region is not too frequent, so that the injection is not suitable to be injected into the same point every time, the injection point and the last injection point are kept at the distance of three fingers, so that the stable absorption of the insulin can be ensured, the delayed absorption is avoided, and the injury of subcutaneous tissues of the injection region caused by the too frequent injection frequency in the same region is avoided.
Hypertension is the most common chronic disease (systolic pressure is more than or equal to 140 mm Hg, diastolic pressure is more than or equal to 90 mm Hg), and is also the most main risk factor of cardiovascular and cerebrovascular diseases, and can be divided into two types in clinical hypertension: 1. essential hypertension accounts for more than 90% of all hypertensive patients, and the cause of the essential hypertension is an independent disease which is not clear. 2. Secondary hypertension, also known as symptomatic hypertension, has a clear cause and may be temporarily or permanently elevated. Hypertension is caused by 1. about 60% of hypertension patients with family history and polygenic inheritance, and 30% -50% of hypertension patients have genetic background. 2. Mental and environmental factors 3. age factors above 40 years of age the incidence is high. 4. Lifestyle factors smoking can accelerate the process of atherosclerosis, a risk factor for hypertension. 5. Effects of drugs 6. effects of other diseases obesity, diabetes, sleep apnea hypopnea syndrome, thyroid disease, renal artery stenosis, renal parenchymal lesions, adrenal space occupying lesions, pheochromocytoma, other neuroendocrine tumors, and the like. On the other hand, hypertension is often combined with other risk factors for cardiovascular and cerebrovascular diseases, such as hypercholesterolemia, obesity, diabetes, etc., to synergistically increase the risk of cardiovascular diseases. Symptomatic administration and long-term control are the most important.
The current treatment of hypertension is divided into three parts: regular exercise, diet control and medication. The medicine for treating hypertension is usually taken regularly for a long time so as to achieve effective treatment and reduce the occurrence of complications such as stroke, heart disease, kidney disease and the like. However, some kinds of hypertension drugs cause side effects and cause discomfort after being taken by patients, so the existing hypertension drugs are adopted after large-scale research and evaluation of curative effect and side effect.
The application of the traditional Chinese medicine composition consisting of turmeric and plantain seeds for treating diabetes and hypertension is not yet available on the market.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides the application of the turmeric and plantain seed composition in preparing the medicinal composition for reducing blood sugar and blood pressure.
The invention also aims to provide an oral pharmaceutical composition for reducing blood sugar and blood pressure.
The technical scheme of the invention is as follows:
the application of the turmeric and plantain seed composition in preparing the pharmaceutical composition for reducing blood sugar and blood pressure is characterized in that the pharmaceutical composition is orally taken, and the turmeric and plantain seed composition consists of plantain seed raw material powder or plantain seed extract and turmeric raw material powder or turmeric extract.
In a preferred embodiment of the present invention, the psyllium seed extract and the turmeric extract are prepared by a method comprising: pulverizing semen plantaginis or Curcuma rhizome, and extracting with ethanol or water at high temperature and high pressure. The high temperature and high pressure water is processed by an Italian coffee machine or other devices with the same temperature control and pressure extraction functions.
Further preferably, in the ethanol-water extraction, the volume ratio of ethanol to water is 1: 10-10: 1.
Further preferably, the temperature of the high-temperature high-pressure water extraction is 80-105 ℃, and the pressure is 14-20 Bar.
In a preferred embodiment of the present invention, the turmeric and psyllium composition is formulated for lowering blood glucose as follows: turmeric original drug powder or turmeric extract 100-; the formula for reducing blood pressure is as follows: turmeric raw medicine powder or turmeric extract 50-1000mg/60kg B.W./day human body, and plantain seed raw medicine powder or plantain seed extract 50-1000mg/60kg B.W./day human body.
The dosage form of the pharmaceutical composition comprises pills, pastilles, capsules, granules, syrups, vials, drops and emulsions, and the components further comprise at least one pharmaceutically acceptable adjuvant, carrier and/or excipient. Furthermore, coffee, chocolate or other natural sweeteners such as licorice or cinnamon may be added to flavor, improve mouthfeel and enhance user preference.
The other technical scheme of the invention is as follows:
an oral pharmaceutical composition for lowering blood sugar and blood pressure comprises Curcuma rhizome and semen plantaginis composition as effective components, wherein the Curcuma rhizome and semen plantaginis composition comprises semen plantaginis crude drug powder or semen plantaginis extract and Curcuma rhizome crude drug powder or Curcuma rhizome extract.
In a preferred embodiment of the present invention, the psyllium seed extract and the turmeric extract are prepared by a method comprising: pulverizing semen plantaginis or Curcuma rhizome, and extracting with ethanol or water at high temperature and high pressure. The high temperature and high pressure water is processed by an Italian coffee machine or other devices with the same temperature control and pressure extraction functions.
Further preferably, in the ethanol-water extraction, the volume ratio of ethanol to water is 1: 10-10: 1.
Further preferably, the temperature of the high-temperature high-pressure water extraction is 80-105 ℃, and the pressure is 14-20 Bar.
In a preferred embodiment of the present invention, the turmeric and psyllium composition is formulated for lowering blood glucose as follows: turmeric original drug powder or turmeric extract 100-; the formula for reducing blood pressure is as follows: turmeric raw medicine powder or turmeric extract 50-1000mg/60kg B.W./day human body, and plantain seed raw medicine powder or plantain seed extract 50-1000mg/60kg B.W./day human body.
The oral pharmaceutical composition can be prepared into pills, lozenges, capsules, granules, syrups, vials, drops and emulsions, and also comprises at least one pharmaceutically acceptable adjuvant, carrier and/or excipient. Furthermore, coffee, chocolate or other natural sweeteners such as licorice or cinnamon may be added to flavor, improve mouthfeel and enhance user preference.
The invention has the beneficial effects that: the turmeric and plantain seed composition has obvious curative effects on reducing blood sugar and blood pressure, and can be used for preparing effective pharmaceutical compositions for treating individuals suffering from diabetes (and) or hypertension.
Drawings
FIG. 1 is a graph showing the response of the oral pharmaceutical composition to the measurement of blood glucose changes in diabetic ICR mice administered with glucose in example 1 of the present invention.
Fig. 2 is a histogram comparing the area under the curve of fig. 1 (AUC in the present invention) in example 1 of the present invention and the blood glucose changes caused by groups of diabetic ICR mice in the combined traditional Chinese medicine test.
FIG. 3 is a bar graph showing the hypotensive effect on normotensive SD rats after a single administration of the oral pharmaceutical composition of example 1 of the present invention.
FIG. 4 is a bar graph of the hypotensive effect on stage I hypertensive P1-HT rats after a single administration of the oral pharmaceutical composition of example 1 of the present invention;
FIG. 5 is a bar graph showing the changes in heart rhythm after administration of the oral pharmaceutical composition of example 1 of the present invention to normotensive SD rats and first-stage hypertensive P1-HT rats.
Detailed Description
The technical solution of the present invention will be further illustrated and described below with reference to the accompanying drawings by means of specific embodiments.
Plantago asiatica Plantago seed (Plantago asiatica) Plantago of the invention has sweet and cold nature and flavor, enters kidney, bladder, liver and lung channels, has the functions of inducing diuresis for treating stranguria, excreting dampness and stopping diarrhea, clearing liver and improving vision, mainly induces diuresis, clears heat, improves vision and eliminates phlegm. It is indicated for dysuria, stranguria with turbid urine, leukorrhagia, hematuria, summer-heat dampness, dysentery, cough with excessive phlegm, damp arthralgia, conjunctival congestion and nebula.
The turmeric (Curcuma longa) used in the present invention is named as Baoding XiangCurcuma of ZingiberaceaeA plant. Pungent and bitter with warm nature. The main indications are blood breaking, qi moving, meridian dredging and pain relieving. Distending pain in chest and abdomen, pain in shoulder and arm, menoxenia, amenorrhea, and traumatic injury. Curcuma rhizome can inhibit hepatitis virus and improve liver parenchymal lesion. Exciting uterus and causing paroxysmal contraction of uterus.
The term "stem, root and whole plant extract" as used herein and the like refers to a mixture obtained by contacting the corresponding parts of the plant with a solvent after breaking the structure (optionally washed) and then using the method of the present invention. The extraction solvent is ethanol water, wherein the volume ratio of ethanol to water can be 1: 10-10: 1, such as 1: 1, 1: 2, 1: 3, 3: 1 or 2: 1. The extract comprises a crude extract (raw extract), more specifically a product obtained by simple extraction, and a treated, purified, refined extract (refined extract), wherein selected plant parts are contacted with at least one extraction solvent, and, optionally, the obtained crude extract may be subjected to one or more separation and/or purification treatments to obtain the refined extract. The stem, root and whole plant extracts may be in liquid form (e.g., solutions, concentrates or distillates) or may be solvent-free solids (e.g., pastes, granules or dried powders) and the solids may be further dissolved in an oil, such as, but not limited to, an edible oil, such as soybean oil.
An effective amount (effective amount) as used herein refers to an amount of a pharmaceutical composition sufficient to produce the desired therapeutic result, wherein the exact nature of the result will vary depending on the particular disease being treated. The specific effective amount will depend upon a variety of factors such as the particular condition being treated, the physiological condition of the patient (e.g., the patient's weight, age or sex), the type of animal being treated, the duration of treatment, the mode of administration, the nature of the current therapy (if any), and the specific formulation and structure of the compound or derivative thereof being used. An effective amount also refers to a compound or composition whose therapeutic benefit exceeds its toxic or deleterious effects. For example, an effective amount may be expressed as the total weight of the drug (e.g., in grams, milligrams, or micrograms) or as the ratio of the weight of the drug to the body weight in milligrams per kilogram (mg/kg).
The pharmaceutical composition used in the present invention means a mixture or compound consisting of two or more substances and containing the extract of the present invention as an active ingredient, whether it is a gas, liquid, powder or solid. The pharmaceutical compositions for oral administration may be in the form of capsules, cachets, pellets, lozenges, powders, granules, or as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as a syrup, or in the form of tablets and the like. In solid dosage forms (capsules, tablets, pills, dragees, powders, granules and other oral dosage forms) of the pharmaceutical composition for oral administration, the composition of the present invention can be used for applications such as the production of foods, pharmaceuticals, industrial materials and the like. Examples of the food of the present invention include nutritional supplement foods, health foods, functional foods, foods for the elderly, and the like.
Example 1
The oral pharmaceutical composition in this example is: is prepared from plantain seed powder and curcuma root powder.
The experimental process comprises the following steps:
1. acute (acute) hypoglycemic ability:
in the evening 23: 00 diabetic ICR mice (starvation for blood glucose > 130mg/dL) were induced by high oil diet to discontinue water and feed for 10 hours. Every morning 9: 00 after measuring the initial blood glucose level, each tube was fed with 0.2mL of the above oral pharmaceutical composition, and then 4g/kg of glucose was administered, and timing was started, and blood glucose was measured once every 30 minutes by a mouse tail vein needle using an Accu-chek (model Instant) blood glucose meter, and five time points of 0, 30, 60, 90, and 120 minutes were measured in total. In the experiment, a blank control group is obtained by feeding 0.2mL of sterilized water before 4g/kg of glucose is given to a diabetic ICR mouse; diabetic ICR mice were given 4g/kg glucose for subcutaneous injection of insulin (insulin) only at 20pM or metformin (clinical drug) at 5mg/kg as two positive control groups. The combination doses in the experimental groups were as follows:
the blood sugar reducing formula comprises:
turmeric: 10-100mg/kg B.W./day 50g ICR diabetic mice, converted into 100-1000mg/60kg B.W./day human;
plantain seed: 100-400mg/kg B.W./day 50g ICR diabetic mice, converted into 1000-4000mg/60kg B.W./day human.
2. Acute (acute) hypotensive ability:
normal blood pressure SD rats and first stage hypertension P1-HT rats were fed on a diet for 10 hours. The initial blood pressure values were monitored and recorded by anesthesia through a gas anesthesia machine, transmitted by PowerLab via femoral cannula to LabChart 7(Colorado Springs CO 80906, USA). After 3 minutes of blood pressure stabilization, each tube was fed 0.2mL of the oral pharmaceutical composition described above and blood pressure and heart rate changes were monitored continuously for 30 minutes after administration. The combined dose is as follows:
the blood pressure reducing formula comprises:
turmeric: 5-100mg/kg of B.W./day 300g of rats, converted into 50-1000mg/60kg of B.W./day of human beings;
plantain seed: 5-100mg/kg B.W./day 300g rat, converted to 50-1000mg/60kg B.W./day human.
(II) experimental results:
the results of this experiment are illustrated below with reference to the drawings of the specification. Data from this experiment are presented as mean ± Standard Error (SE) and are significantly analyzed using one-way ANOVA with Tukey test to determine pre-treatment and post-treatment differences and histograms are constructed with GraphPad Prism 7.04(La Jolla, CA, USA). (p < 0.05),. times (p < 0.001) and. times (p < 0.0001) are statistically significant levels.
As shown in FIG. 1, the blood glucose level of diabetic ICR mice administered with only 4g/kg glucose increased to the maximum level after 30 minutes, and was significantly slower than that of either the experimental group or the control group, which was followed by a decrease in blood glucose level. The blood glucose values of the diabetic ICR mice fed with the metformin and the oral pharmaceutical composition after 30 minutes by subcutaneous insulin injection are all increased slowly relative to the blank control group, and the subsequent blood glucose values are reduced in a significantly faster way relative to the blank control group. Therefore, the oral pharmaceutical composition has the efficacy of reducing blood sugar, and the effect is similar to that of common blood sugar reducing drugs, namely insulin and metformin.
As shown in fig. 2, the data in fig. 1 is converted into a histogram, and then the effects of different processing methods on blood glucose changes can be more clearly compared. Accordingly, the oral pharmaceutical composition has a blood sugar lowering effect superior to that of metformin.
As shown in FIGS. 3 to 5, the results of FIG. 3 show that the blood pressure of normal blood pressure SD rats did not change abruptly 30 minutes after taking the oral pharmaceutical composition. Therefore, the oral pharmaceutical composition can not cause abnormal blood pressure for individuals with normal blood pressure; FIG. 4 shows that the systolic blood pressure of the first stage hypertension P1-HT rat is significantly decreased after 30 minutes of taking the oral pharmaceutical composition, so that the oral pharmaceutical composition has the effect of lowering blood pressure for hypertensive individuals; the results in FIG. 5 show that the heart rate of normal blood pressure SD rats and first stage hypertension P1-HT rats has not been changed significantly after taking the oral pharmaceutical composition for 30 minutes.
According to the experimental result, the oral pharmaceutical composition not only can be used for preparing the medicines or the compositions for reducing blood pressure and blood sugar, but also can be used for preparing daily health-care food after evaluation.
The above description is only a preferred embodiment of the present invention, and therefore should not be taken as limiting the scope of the invention, which is defined by the appended claims.

Claims (10)

1. The application of the turmeric and plantain seed composition in preparing the medicine composition for reducing blood sugar and blood pressure is characterized in that: the pharmaceutical composition is administered orally, and the turmeric and plantain seed composition is composed of plantain seed crude drug powder or plantain seed extract and turmeric root crude drug powder or turmeric extract.
2. The use of claim 1, wherein: the preparation method of the plantain seed extract and the turmeric extract comprises the following steps: pulverizing semen plantaginis or Curcuma rhizome, and extracting with ethanol or water at high temperature and high pressure.
3. Use according to claim 2, characterized in that: in the ethanol-water extraction, the volume ratio of ethanol to water is 1: 10-10: 1.
4. Use according to claim 2, characterized in that: the temperature of the high-temperature high-pressure water extraction is 80-105 ℃, and the pressure is 14-20 Bar.
5. The use according to any one of claims 1 to 4, wherein: the turmeric and plantain seed composition is used for reducing blood sugar and comprises the following formula: turmeric original drug powder or turmeric extract 100-; the formula for reducing blood pressure is as follows: turmeric raw medicine powder or turmeric extract 50-1000mg/60kg B.W./day human body, and plantain seed raw medicine powder or plantain seed extract 50-1000mg/60kg B.W./day human body.
6. An oral pharmaceutical composition for reducing blood sugar and blood pressure, which is characterized in that: the active ingredients of the composition comprise turmeric and plantain seed composition, and the turmeric and plantain seed composition consists of plantain seed raw material powder or plantain seed extract and turmeric raw material powder or turmeric extract.
7. The oral pharmaceutical composition of claim 6, wherein: the preparation method of the plantain seed extract and the turmeric extract comprises the following steps: pulverizing semen plantaginis or Curcuma rhizome, and extracting with ethanol or water at high temperature and high pressure.
8. The oral pharmaceutical composition of claim 7, wherein: in the ethanol-water extraction, the volume ratio of ethanol to water is 1: 10-10: 1.
9. The oral pharmaceutical composition of claim 7, wherein: the temperature of the high-temperature high-pressure water extraction is 80-105 ℃, and the pressure is 14-20 Bar.
10. The oral pharmaceutical composition of any one of claims 6 to 8, wherein: the turmeric and plantain seed composition is used for reducing blood sugar and comprises the following formula: turmeric original drug powder or turmeric extract 100-; the formula for reducing blood pressure is as follows: turmeric raw medicine powder or turmeric extract 50-1000mg/60kg B.W./day human body, and plantain seed raw medicine powder or plantain seed extract 50-1000mg/60kg B.W./day human body.
CN201910896486.4A 2019-09-20 2019-09-20 Application of turmeric and plantain seed composition in preparation of pharmaceutical composition for reducing blood sugar and blood pressure Pending CN111773352A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910896486.4A CN111773352A (en) 2019-09-20 2019-09-20 Application of turmeric and plantain seed composition in preparation of pharmaceutical composition for reducing blood sugar and blood pressure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910896486.4A CN111773352A (en) 2019-09-20 2019-09-20 Application of turmeric and plantain seed composition in preparation of pharmaceutical composition for reducing blood sugar and blood pressure

Publications (1)

Publication Number Publication Date
CN111773352A true CN111773352A (en) 2020-10-16

Family

ID=72755051

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910896486.4A Pending CN111773352A (en) 2019-09-20 2019-09-20 Application of turmeric and plantain seed composition in preparation of pharmaceutical composition for reducing blood sugar and blood pressure

Country Status (1)

Country Link
CN (1) CN111773352A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102225095A (en) * 2011-06-23 2011-10-26 上海中医药大学 Effective fraction of plantain seeds as well as preparation method and application thereof
CN103989752A (en) * 2014-05-13 2014-08-20 高伦 Pharmaceutical composition used for preventing and treating diabetes mellitus combined with hypertension
CN107669991A (en) * 2017-11-24 2018-02-09 成都中医药大学附属医院 A kind of pharmaceutical composition for reducing serum uric acid level and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102225095A (en) * 2011-06-23 2011-10-26 上海中医药大学 Effective fraction of plantain seeds as well as preparation method and application thereof
CN103989752A (en) * 2014-05-13 2014-08-20 高伦 Pharmaceutical composition used for preventing and treating diabetes mellitus combined with hypertension
CN107669991A (en) * 2017-11-24 2018-02-09 成都中医药大学附属医院 A kind of pharmaceutical composition for reducing serum uric acid level and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
孙林林等: "姜黄化学成分及药理作用研究进展"，，", 《山东中医药大学学报》 *
陈信云等: "《中药学 第3版》", 2017013, 中国医药科技出版社 *

Similar Documents

Publication Publication Date Title
CN102526479B (en) Health-care medicine formula with functions of enhancing immunity and lowering blood sugar
CN102526478B (en) Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar
CN107080250A (en) A kind of composition of auxiliary hyperglycemic, beverage and preparation method thereof
CN102271698A (en) Pharmaceutical composition and use for preparing medicament thereof
CN101190280B (en) Use of extract of non-fruit part of prune tree
JP2011522844A (en) Composition for reducing blood glucose level and use thereof
CN111166820B (en) Traditional Chinese medicine composition containing fingered citron, preparation and application
CN108403818B (en) Composition for assisting in reducing blood sugar and application thereof
CN110051817A (en) A kind of Chinese traditional medicine composition and its application reducing uric acid
CN101474346B (en) Longstamen onion bulb extract as well as preparation method and application thereof
CN107281386B (en) Method for preparing medicine for treating hypertension by using dendrobium officinale and radish seeds and application
KR100601191B1 (en) Hypoglycemic agents
CN111281902A (en) Application of lithocarpus litseifolius or active extract thereof
CN111773352A (en) Application of turmeric and plantain seed composition in preparation of pharmaceutical composition for reducing blood sugar and blood pressure
CN111773315A (en) Application of spiranthes sinensis extract in preparation of pharmaceutical composition for treating hypertension
CN111773351A (en) Application of coleus blumei and curcuma longa composition in preparation of medicine composition for reducing blood sugar and blood pressure
CN111773274A (en) Application of coleus blumei and plantain seed composition in preparation of pharmaceutical composition for reducing blood sugar and blood pressure
CN103181945B (en) The purposes of Semen Luffae
JP2000342228A (en) Formulated tea of smallanthus sonchifol with mulberry leaf
CN103721074B (en) Pharmaceutical composition and preparation method and application thereof
CN107126450B (en) A Chinese medicinal preparation containing extract and effective substance, and its preparation method and application
JP3610340B2 (en) Functional food for suppressing blood sugar or blood pressure rise
CN111773208A (en) Application of garcinia fruit extract gamma-mangostin in preparation of pharmaceutical composition for reducing blood sugar and blood pressure
CN104256618A (en) Food, health care product or medicine composition with blood sugar reduction function
CN113440536B (en) Medicine for preventing and treating diabetes and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20201016